How to use Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) initial dose (1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units of hyaluronidase) 15 mL, administered subcutaneously over approximately 8 minutes ; Subsequently, a 10mL maintenance dose of Phesgo (600mg pertuzumab, 600mg trastuzumab and 20,000 units of hyaluronidase) was administered every 3 weeks, administered subcutaneously for approximately 5 minutes. Phesgo dosage does not need to be adjusted based on patient weight or concomitant chemotherapy regimen.

(1) Neoadjuvant treatment of breast cancer: As part of the treatment regimen for early-stage breast cancer, give Phesgo every 3 weeks for 3-6 cycles. After surgery, patients should continue to receive Phesgo for 1 year of treatment (up to 18 cycles) or until disease recurrence or uncontrollable toxicity, whichever occurs first, as part of a complete treatment regimen for early-stage cancer.

(2) Adjuvant treatment of breast cancer: Take Phesgo every 3 weeks for 1 year (up to 18 cycles) or until disease recurrence or uncontrolled toxicity, whichever occurs first, as part of a complete regimen for early-stage cancer, including standard anthracycline and/or taxane chemotherapy. StartPhesgo on day 1 of the first taxane-containing cycle.

(3) Metastatic breast cancer: When administered with Phesgo, the recommended initial dose of docetaxel is 75 mg/m2 administered as an intravenous infusion. If the initial dose is well tolerated, the dose may be increased to 100 mg/m2 every 3 weeks. TakePhesgo until disease progression or uncontrollable toxicity, whichever occurs first.

The original Phesgo drug is not marketed in the country and therefore cannot be included in medical insurance. Since Phesgo's original drug has been on the market overseas for a short time, there is less price and other related information. For specific prices and drug information, please consult Yaode's medical consultant.